CAU
LGND icon

Caxton Associates (UK)’s Ligand Pharmaceuticals LGND Stock Holding History

Caxton Associates (UK)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.72M Buy
18,651
+4,143
+29% +$820K 0.08% 94
2025
Q4 		$2.74M Hold
14,508
– – 0.05% 137
2025
Q3 		$2.57M Buy
+14,508
New +$2.16M 0.06% 149

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Caxton Associates (UK)'s LGND Position: Q1 2026 in Review

Caxton Associates (UK) increased its Ligand Pharmaceuticals (LGND) stake by 29% in Q1 2026, buying an estimated $820K and bringing the position to 18,651 shares worth $3.72M. The position accounts for 0.08% of the portfolio, ranked #94.

Caxton Associates (UK) first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Caxton Associates (UK) held 18,651 shares of Ligand Pharmaceuticals worth $3.72M as of Q1 2026.
  • Caxton Associates (UK) bought 4,143 Ligand Pharmaceuticals shares in Q1 2026, an estimated $820K.
  • Ligand Pharmaceuticals made up 0.08% of Caxton Associates (UK)'s portfolio in Q1 2026, its #94 holding.
  • Caxton Associates (UK) first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.